Antibiotic Resistance Rapidly Rising in Ancient Deadly Bacteria

Researchers are raising concerns about the rapid rise of antibiotic resistance in a long-known, deadly pathogen. This accelerating trend threatens to undermine current treatments and poses serious challenges for global public health efforts.

Forgotten Menace Returns: Typhoid’s Global Threat Reignites

Once considered a relic of the past in much of the developed world, typhoid fever has reemerged as a pressing public health threat. This infectious disease, caused by the bacterium Salmonella enterica serovar Typhi, had been effectively managed for decades thanks to antibiotics. However, recent trends indicate a dramatic shift: rising antibiotic resistance is rapidly undermining those therapeutic victories.

The Surge of Superbugs

A comprehensive international study released in 2022 analyzed the genomes of nearly 3,500 S Typhi strains collected from 2014 to 2019 across South Asia—specifically Nepal, Bangladesh, Pakistan, and India. The findings were sobering: so-called XDR (extensively drug-resistant) strains are now commonplace. These variants not only shrug off traditional treatments like ampicillin and trimethoprim-sulfamethoxazole but have also developed resistance to more modern drugs, including third-generation cephalosporins and fluoroquinolones.

The phenomenon is no longer confined to its historical hotspots. Almost 200 cases have surfaced outside South Asia since the 1990s, affecting regions as diverse as Africa and countries such as the United Kingdom, the United States, and Canada. As infectious diseases expert Jason Andrews at Stanford University remarked, “The speed at which these highly resistant strains are emerging and spreading is alarming.”

Treatment Options Dwindling Fast

Currently, azithromycin—a macrolide—remains one of the last reliable oral options against resistant typhoid. Worryingly, initial signs of resistance to this drug have already appeared. Should this trend continue, effective treatment may soon become unattainable. Without access to appropriate therapy, up to one in five cases could prove fatal—a troubling statistic given that over 13 million global infections were estimated in 2024 alone.

Several factors explain why experts insist on immediate action:

• Expanded vaccination: Conjugate vaccines can curb outbreaks and are now recommended for children in high-risk nations.
• Tighter surveillance: Strengthening global monitoring helps contain cross-border spread early on.
• Sustained research: Investment in developing new antibiotics is crucial given bacterial evolution.

A Global Response Cannot Wait

South Asia remains ground zero for typhoid—accounting for roughly 70% of cases worldwide—but other regions are increasingly affected. Some countries are stepping up: Pakistan’s nationwide childhood vaccination campaign stands out as an example to emulate. The World Health Organization (WHO), with support from four recently approved vaccines according to April 2025 CDC data, urges rapid adoption wherever typhoid persists.

If recent pandemics taught us anything, it’s that infectious threats ignore borders. Rapid adaptation and decisive global cooperation are now essential—not just for typhoid, but to stem the broader tide of antimicrobial resistance before it’s too late.